| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/20/2001 | US6190698 Stability; discoloration inhibition; used as antipsychotic agent |
| 02/20/2001 | CA2302629C Estrogen receptor |
| 02/20/2001 | CA2192289C Substituted heterocyclic derivatives |
| 02/15/2001 | WO2001011085A2 Bdnf polymorphism and association with bipolar disorder |
| 02/15/2001 | WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY |
| 02/15/2001 | WO2001010900A2 Globular assembly of amyloid beta protein and uses thereof |
| 02/15/2001 | WO2001010893A2 Il-16 antagonists |
| 02/15/2001 | WO2001010884A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene |
| 02/15/2001 | WO2001010867A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010846A2 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010831A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 02/15/2001 | WO2001010829A1 Novel vitamin d analogues |
| 02/15/2001 | WO2001010816A2 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 02/15/2001 | WO2001010457A2 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010445A1 Neuropathy remedies |
| 02/15/2001 | WO2001010444A2 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | WO2001010433A1 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 02/15/2001 | WO2001010432A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 02/15/2001 | WO2001010431A2 Headache and colic relief composition with asafetida and method of use thereof |
| 02/15/2001 | WO2001010430A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 02/15/2001 | WO2001010426A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010380A2 Benzanilides as potassium channel openers |
| 02/15/2001 | WO2001010378A2 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/15/2001 | WO2001010323A1 Method of controlling body temperature while reducing shivering |
| 02/15/2001 | WO2001010221A1 Vaccines for the treatment of autoimmune disease |
| 02/15/2001 | WO2001010203A2 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 02/15/2001 | WO2000078288A3 Novel process for paroxetine compositions |
| 02/15/2001 | WO2000069900A3 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000066584B1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/15/2001 | WO2000066109A3 Intravenous valproate for acute treatment of migraine headache |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000057900A3 Factor for regulation of neurite growth |
| 02/15/2001 | WO2000054759A3 Lxr modulators |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000043419A3 Exocytosis pathway proteins and methods of use |
| 02/15/2001 | WO2000011204A3 Homer interacting proteins |
| 02/15/2001 | WO1999042102A8 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 02/15/2001 | DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases |
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | DE19936521A1 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate Substituted pyrrolidine-2,3,4-trione-3-oxime Derivatives |
| 02/15/2001 | CA2403910A1 Headache and colic relief composition with asafetida and method of use thereof |
| 02/15/2001 | CA2388341A1 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 02/15/2001 | CA2382759A1 Agent for the remedy of neural damage having a nitrogen-containing compound as the active ingredient |
| 02/15/2001 | CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | CA2381910A1 Novel vitamin d analogues |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2380973A1 Substituted pyrrolidine-2-3,4-trione 3-oxime derivatives which are active as nmda receptor antagonists |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2378955A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 02/15/2001 | CA2378481A1 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | CA2378480A1 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | CA2378401A1 Implantable active ingredient depot |
| 02/15/2001 | CA2378315A1 Neuropathy therapeutic agent |
| 02/15/2001 | CA2378285A1 Vaccines for the treatment of autoimmune disease |
| 02/15/2001 | CA2378241A1 Benzanilides as potassium channel openers |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/15/2001 | CA2348959A1 Methods of cytoprotection using an enantiomer of estrogen of ischemic damage |
| 02/15/2001 | CA2346291A1 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/14/2001 | EP1075840A2 Therapeutic and prophylactic uses of antithrombin III |
| 02/14/2001 | EP1075535A1 A method for diagnosing and treating chronic pelvic pain syndrome |
| 02/14/2001 | EP1075529A1 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 02/14/2001 | EP1075528A1 Endothelin-converting-enzyme like protein |
| 02/14/2001 | EP1075494A2 Compounds and methods for modulating nonclassical cadherin-mediated functions |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075490A1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 02/14/2001 | EP1075489A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues |
| 02/14/2001 | EP1075478A1 Phenylurea and phenylthio urea derivatives |
| 02/14/2001 | EP1075476A1 Novel benzimidazoles and benzoxazoles |
| 02/14/2001 | EP1075475A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 02/14/2001 | EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| 02/14/2001 | EP1075471A1 Indolyl derivatives as serotonergic agents |
| 02/14/2001 | EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 02/14/2001 | EP1075466A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 02/14/2001 | EP1075270A1 Short peptides for treatment of neurological degenerative diseases |
| 02/14/2001 | EP1075264A1 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol |
| 02/14/2001 | EP1075263A1 Aqueous process for manufacturing paroxetine solid dispersions |
| 02/14/2001 | EP1075256A1 Arylhydrocarbon receptor ligand antagonists |
| 02/14/2001 | EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 02/14/2001 | EP0983380A4 Methods for treating bipolar mood disorder associated with markers on chromosome 18q |
| 02/14/2001 | EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response |
| 02/14/2001 | EP0842170B1 Diphenylmethylene piperidine derivatives |
| 02/14/2001 | EP0833820B1 Benzisoxazole and indazole derivatives as antipsychotic agents |
| 02/14/2001 | CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity |
| 02/14/2001 | CN1284076A 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof |
| 02/14/2001 | CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability |
| 02/14/2001 | CN1284066A Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 02/14/2001 | CN1284064A 2,3-substituted indole compounds as cox-2 inhibitors |
| 02/14/2001 | CN1284058A Neuroprotective agents |